Orthocell Achieves First Canadian Sales of Remplir™ in $75M Nerve Repair Market
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has recorded its first commercial sales of Remplir™ in Canada, following Health Canada approval and distributor appointments. The company is expanding its North American footprint, with Canada's $75 million nerve repair market and the US's $1.6 billion market. The distributor-led model allows Orthocell to focus on the larger US market while leveraging established hospital and surgeon relationships in Canada.
Topics: distribution strategy market expansion medical devices nerve repair sales milestones